Red Clover and Bone Density

Bone loss after menopause is real, fast and consequential. In the few years surrounding the final menstrual period, women can lose bone at several times their previous rate, and the fractures that follow — particularly hip fractures — carry serious consequences for independence and survival. It is therefore entirely understandable that a herb marketed as a natural source of plant estrogen would be looked at as a possible bone protector.

The evidence for that is weaker than the marketing implies, and the reason is instructive. Bone research uses three very different kinds of endpoint, and supplement claims routinely slide between them as if they were the same thing. This page keeps them separate: what red clover does to bone turnover markers (a blood or urine chemistry measurement), what it does to bone mineral density (an actual scan), and what it does to fractures (the only endpoint anyone truly cares about). Red clover has some evidence for the first, weak and conflicting evidence for the second, and no evidence at all for the third.

Table of Contents

  1. Why Bone Is Lost After Menopause
  2. How Estrogen Protects Bone
  3. Three Endpoints That Are Not the Same Thing
  4. What Isoflavones Do to Bone Cells
  5. Animal Studies
  6. The Human Density Trials
  7. Fermented Extracts and the Osteopenia Trial
  8. Pooled Analyses Across Isoflavone Formulations
  9. What Actually Protects Bone
  10. The Honest Verdict
  11. Key Research Papers
  12. Safety and Disclaimer
  13. Connections

Why Bone Is Lost After Menopause

Bone is not inert scaffolding. It is continuously demolished and rebuilt by two cell populations working in opposition: osteoclasts, which dissolve old bone, and osteoblasts, which lay down new bone. In a healthy adult these are roughly balanced, and the whole skeleton is quietly replaced over about a decade.

Estrogen is one of the principal brakes on the demolition side. When estrogen falls at menopause, osteoclasts live longer and work harder, the rebuilding side cannot keep pace, and net bone is lost. The loss is not gradual and even — it accelerates sharply in the years around the final period, with the fastest phase typically spanning the year before through several years after, and then settles to a slower age-related decline.

Trabecular bone — the sponge-like interior found in the spine, hip and wrist — is metabolically busier than the dense cortical shell and is lost first. That is why vertebral and wrist fractures show up earlier in the sequence and hip fractures later. It also means the spine is where a bone-density study will detect a change soonest, which is why trials measure it there.

How Estrogen Protects Bone

Estrogen restrains bone resorption through several routes. It reduces the production of signalling molecules that recruit and activate osteoclasts, increases the decoy receptor that intercepts the principal osteoclast-activating signal, and promotes osteoclast death once their work is done. It also supports osteoblast survival. The net effect is a slower, better-coupled remodelling cycle.

Hormone therapy demonstrates this convincingly: it reduces bone loss and, in randomized trials, reduces fractures — a point covered on Bone Loss Prevention and HRT. Evidence tier: large randomized clinical trials with fracture endpoints.

The question for red clover is whether a weak plant estrogen, acting mainly at estrogen receptor beta and at a small fraction of estradiol's potency, can reproduce any clinically useful share of that. Bone cells do carry estrogen receptor beta, so the target exists. Whether the signal is strong enough is exactly what the trials were built to find out.

Three Endpoints That Are Not the Same Thing

This section is the key to reading any bone supplement claim critically.

  1. Bone turnover markers. Blood or urine measurements of fragments released as bone is broken down or built — collagen crosslinks such as CTX and NTX for resorption, P1NP and bone-specific alkaline phosphatase for formation. They respond within weeks, which makes them cheap and convenient for short trials. They are a snapshot of activity, not a measure of how much bone you have.
  2. Bone mineral density (BMD). Measured by DXA scan, usually at the lumbar spine and hip. This is an actual quantity of mineral. It moves slowly — a study generally needs at least a year to detect a real change — and it is a far better predictor of fracture than turnover markers.
  3. Fractures. The outcome that matters. Detecting a fracture difference requires thousands of participants followed for years. No red clover trial has ever come close to that scale.

The gap between markers and fractures is not hypothetical. Drugs have been developed that moved turnover markers in the desired direction and then failed, or caused harm, when tested against real outcomes. A supplement that shifts a bone marker over twelve weeks has demonstrated biological activity. It has not demonstrated that it prevents a single broken bone. Every marketing claim built on marker data should be read with that sentence in mind.

What Isoflavones Do to Bone Cells

In cell culture, isoflavones including genistein and daidzein — the two active products of red clover's biochanin A and formononetin — show effects consistent with a mild estrogenic action on bone: reduced osteoclast formation and activity, and in some systems support for osteoblast differentiation. Biochanin A and formononetin themselves have been studied directly in bone cell models with broadly similar findings.

These results are genuinely interesting and genuinely limited. Cell-culture experiments use concentrations that may exceed what a capsule produces in human blood, they bypass digestion and liver metabolism entirely, and isolated bone cells behave differently from bone in a living skeleton subject to mechanical loading and systemic hormones. A useful entry point to this literature is a PubMed topic search on biochanin A, formononetin and bone cells. Evidence tier: preliminary, in vitro.

Animal Studies

The standard animal model for postmenopausal bone loss is the ovariectomized rat, which loses bone rapidly once its ovaries are removed. Red clover isoflavones have been tested in it. Effects of phytoestrogenic isoflavones from red clover (Trifolium pratense L.) on experimental osteoporosis (Phytotherapy Research, 2007) examined red clover isoflavones in this model — find it on PubMed. Related work, Effect of an isoflavones-containing red clover preparation and alkaline supplementation on bone metabolism in ovariectomized rats (Clinical Interventions in Aging, 2009), tested a red clover preparation on bone metabolism in the same model — find it on PubMed. Evidence tier: preliminary, animal.

Animal bone studies are a reasonable screening step and a poor basis for a human claim. Rodents lose bone far faster than women do, doses per kilogram are often much higher than a human supplement provides, and the ovariectomized rat has an unhappy history of predicting benefits that did not replicate in people. These studies justify running human trials. They do not substitute for them — and in red clover's case, the human trials were run.

The Human Density Trials

The single most important human study is The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial (The American Journal of Clinical Nutrition, 2004). It gave red-clover-derived isoflavones or placebo for one full year and measured bone mineral density by DXA — the right endpoint, over an adequate duration, in a properly blinded design. Overall it found no clear, convincing benefit on bone density. Find it on PubMed. Evidence tier: randomized clinical trial, largely negative.

This trial is the reason the honest summary of red clover and bone is negative rather than open. When the best-designed study using the best available surrogate endpoint over a full year finds nothing convincing, shorter studies using softer endpoints cannot overturn it.

Earlier and smaller work had been more encouraging. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism (Menopause, 2001) reported favourable movement in some bone and lipid measures — find it on PubMed. It was small and short, and it is the kind of preliminary result that larger trials exist to test. Evidence tier: small randomized trial, positive, not replicated at scale.

A shorter modern study, Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women (Evidence-Based Complementary and Alternative Medicine, 2015), reported improvement in bone measures over twelve weeks — find it on PubMed. Twelve weeks is far too short for a meaningful density change; results over that horizon are dominated by turnover markers, with all the interpretive limits described above. Evidence tier: short randomized trial, surrogate endpoints.

Fermented Extracts and the Osteopenia Trial

The most substantive positive human bone result comes from the fermented-extract line of research. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial (The American Journal of Clinical Nutrition, 2017) used a fermented red clover extract in women who already had osteopenia — reduced bone density short of osteoporosis — and reported reduced bone mineral density loss compared with placebo, together with changes in estrogen metabolism. Find it on PubMed. Evidence tier: randomized clinical trial, positive, single and small.

The logic behind fermenting is the same as on the menopause page: fermentation converts the plant's isoflavones into more bioavailable and more receptor-active forms during manufacture, rather than relying on the individual's gut bacteria to do it. If bioavailability is what earlier trials lacked, a fermented product might succeed where a conventional extract failed.

Three cautions apply, and they are not small. The trial was modest in size and has not been independently replicated by other groups. It measured density change over months, not fractures. And the product tested is a specific fermented preparation, not the standard red clover extract sold in most shops — buying an ordinary bottle on the strength of this study means buying something that was not what the study tested.

Pooled Analyses Across Isoflavone Formulations

A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women (The American Journal of Clinical Nutrition, 2017) pooled isoflavone bone data across different formulations and treated formulation and bioavailability as the central variable rather than a nuisance — find it on PubMed. Evidence tier: systematic review of randomized trials.

That framing is the most useful contribution the pooled literature makes. It suggests that "do isoflavones help bone?" may be the wrong question, and that "which isoflavone preparation, delivering which metabolites, to whom?" is the right one. It is also, at present, an unanswered question — and an unanswered question is not a reason to buy anything.

A caveat on reading this literature: much of the isoflavone bone research involves soy-derived preparations rather than red clover. Those trials are legitimate scientific context for how isoflavones behave in bone, but they are not evidence about red clover specifically, and pooled analyses that mix sources should be read with that in mind.

What Actually Protects Bone

Because the red clover evidence is weak, it is worth being concrete about what is not weak. Anyone genuinely concerned about bone loss should be spending their attention here.

A DXA scan is how you find out where you actually stand. Guessing, or hoping a supplement is handling it, is the failure mode this section exists to prevent.

The Honest Verdict

Red clover is not an established treatment for osteoporosis or osteopenia, and should not be relied on as one. The one substantial year-long randomized trial measuring actual bone mineral density found no clear benefit. The positive human results come from small, short studies, from surrogate markers, or from a specific fermented preparation tested once and not independently replicated. No red clover study has ever measured a fracture.

The fermented-extract osteopenia result is the strongest thing the herb has, and it is worth watching rather than acting on. If replication confirms it, the picture changes. Until then, the honest position is that red clover might turn out to be a minor supporting player in bone health, and is certainly not a foundation.

The practical risk here is not that red clover harms bone. It is that someone at genuine fracture risk takes a supplement, feels they have addressed the problem, and does not get the scan, the exercise programme or the prescription that would actually have helped. That substitution is the real harm.

Key Research Papers

  1. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial — The American Journal of Clinical Nutrition, 2004. The one-year density trial; largely negative. Find on PubMed
  2. Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial — The American Journal of Clinical Nutrition, 2017. Find on PubMed
  3. A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women — The American Journal of Clinical Nutrition, 2017. Find on PubMed
  4. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism — Menopause, 2001. Find on PubMed
  5. Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women — Evidence-Based Complementary and Alternative Medicine, 2015. Find on PubMed
  6. Effects of phytoestrogenic isoflavones from red clover (Trifolium pratense L.) on experimental osteoporosis — Phytotherapy Research, 2007. Animal model. Find on PubMed
  7. Effect of an isoflavones-containing red clover preparation and alkaline supplementation on bone metabolism in ovariectomized rats — Clinical Interventions in Aging, 2009. Animal model. Find on PubMed
  8. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? — The Journal of Steroid Biochemistry and Molecular Biology, 2005. Receptor pharmacology background. Find on PubMed
  9. Equol: history, chemistry, and formation — The Journal of Nutrition, 2010. Why bioavailability may differ between individuals. Find on PubMed
  10. PubMed topic search: biochanin A formononetin osteoblast osteoclast bone — the cell-level literature. Run this search
  11. PubMed topic search: Trifolium pratense bone mineral density randomized — the full human bone record. Run this search

Back to Table of Contents

Safety and Disclaimer

Red clover is a phytoestrogen and carries the cautions that follow from that: avoid in pregnancy and breastfeeding; use only after medical advice with a history of breast, uterine or ovarian cancer, endometriosis or uterine fibroids; discuss with a doctor if taking anticoagulant or antiplatelet medication, hormone therapy, tamoxifen or an aromatase inhibitor; and stop roughly two weeks before scheduled surgery. Full detail is on Red Clover Isoflavones, Hormones and Safety. If you are worried about bone loss, ask your doctor about a DXA scan and a fracture-risk assessment — do not substitute a supplement for that conversation. This page is educational information, not medical advice.

Connections

Back to Table of Contents